Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IPILIMUMAB Cause Vitamin d deficiency? 11 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Vitamin d deficiency have been filed in association with IPILIMUMAB (YERVOY). This represents 0.0% of all adverse event reports for IPILIMUMAB.

11
Reports of Vitamin d deficiency with IPILIMUMAB
0.0%
of all IPILIMUMAB reports
0
Deaths
5
Hospitalizations

How Dangerous Is Vitamin d deficiency From IPILIMUMAB?

Of the 11 reports, 5 (45.5%) required hospitalization, and 1 (9.1%) were considered life-threatening.

Is Vitamin d deficiency Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IPILIMUMAB. However, 11 reports have been filed with the FAERS database.

What Other Side Effects Does IPILIMUMAB Cause?

Death (3,710) Malignant neoplasm progression (3,296) Diarrhoea (2,557) Off label use (2,097) Colitis (1,988) Pyrexia (1,796) Rash (1,556) Fatigue (1,447) Intentional product use issue (1,329) Nausea (1,169)

What Other Drugs Cause Vitamin d deficiency?

EMTRICITABINE\TENOFOVIR DISOPROXIL (1,029) EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL (639) ALENDRONATE (500) TENOFOVIR DISOPROXIL (467) ADALIMUMAB (426) COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL (392) EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL (367) METHOTREXATE (241) ETANERCEPT (226) FINGOLIMOD (224)

Which IPILIMUMAB Alternatives Have Lower Vitamin d deficiency Risk?

IPILIMUMAB vs IPRAGLIFLOZIN L-PROLINE IPILIMUMAB vs IPRATROPIUM IPILIMUMAB vs IPRATROPIUM\IPRATROPIUM ANHYDROUS IPILIMUMAB vs IPTACOPAN IPILIMUMAB vs IRBESARTAN

Related Pages

IPILIMUMAB Full Profile All Vitamin d deficiency Reports All Drugs Causing Vitamin d deficiency IPILIMUMAB Demographics